MAPT and Alzheimer disease: Third, since preclinical AD is a designation for individuals who exhibit pathological amyloid-β and tau deposits, it is critical to collect data on these biomarkers and direct evidence of cholinergic neurodegeneration in our future research, which may benefit a better understanding of the directionality between reports of SCD and BF atrophy.